SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

$GKOS
Medical/Dental Instruments
Health Care
Get the next $GKOS alert in real time by email
SC 13G/A 1 tm236668d1_sc13ga.htm SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

(Amendment No. 7)*

 

Under the Securities Exchange Act of 1934

 

GLAUKOS CORPORATION

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

377322102

(CUSIP Number)

 

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨Rule 13d-1(b)
¨Rule 13d-1(c)
xRule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

CUSIP No. 377322102

 

SCHEDULE 13G Page 2 of 5 Pages

 

1

NAMES OF REPORTING PERSONS

 

Thomas W. Burns

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)      ¨

(b)      ¨

3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

USA

 

 

NUMBER OF

 

SHARES

 

BENEFICIALLY

 

OWNED BY

 

EACH

 

REPORTING

 

PERSON WITH 

5

SOLE VOTING POWER

 

2,707,641(1)

 

6

SHARED VOTING POWER

 

100,000(2)

 

7

SOLE DISPOSITIVE POWER

 

2,707,641(1)

 

8

SHARED DISPOSITIVE POWER

 

100,000(2)

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,807,641

 

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES           ¨

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5.71%(3)

 

12

TYPE OF REPORTING PERSON

 

IN

 

   

(1)Includes (i) 1,378,261 shares issuable upon the exercise of options that are currently exercisable or will vest and become exercisable, and shares that will be delivered upon the vesting of restricted stock units, within 60 days of December 31, 2022, (ii) 593,426 shares held by Mr. Burns, (iii) 238,107 shares held by the Burns Annuity Trust as of December 31, 2022, of which Mr. Burns is a beneficiary and co-Trustee, (iii) 120,000 shares held by the Burns Charitable Remainder Trust as of December 31, 2022, of which Mr. Burns is a beneficiary and co-Trustee, (iv) 277,847 shares held by the Burns Family Trust as of December 31, 2022, of which Mr. Burns is a beneficiary and co-Trustee and (v) 100,000 shares held by the Thomas W. Burns Irrevocable Trust as of December 31, 2022, of which Mr. Burns is a beneficiary.

 

(2)Represents 100,000 shares held by the Janet M. Burns Irrevocable Trust as of December 31, 2022, of which Mr. Burns is trustee and Mr. Burns’ spouse is a beneficiary.

 

(3)Based upon 47,754,475 shares of Glaukos Corporation common stock outstanding at December 31, 2022.

 

 

 

 

CUSIP No. 377322102

 

SCHEDULE 13G Page 3 of 5 Pages

 

Item 1(a)

Name of Issuer:

 

Glaukos Corporation (“Issuer”)

 

Item 1(b)Address of Issuer’s Principal Executive Offices:

 

1 Glaukos Way, Aliso Viejo, CA 92656

 

Item 2(a)Name of Person Filing:

 

Thomas W. Burns

 

Item 2(b)Address of Principal Business Office or, If None, Residence

 

Same as Item 1(b)

 

Item 2(c)Citizenship

 

See Row 4 of cover page

 

Item 2(d)

Title of Class of Securities:

 

Common stock, $0.001 par value per share

 

Item 2(e)CUSIP Number:

377322102

 

Item 3.

Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c):

 

Not applicable.

 

Item 4.Ownership

 

(a)Amount Beneficially Owned: See Row 9 of cover page.

 

(b)Percent of Class. See Row 11 of cover page.

 

(c)Number of shares as to which the person has:

 

i.Sole power to vote or to direct the vote: See Row 5 of cover page.

 

ii.Shared power to vote or to direct the vote: See Row 6 of cover page.

 

iii.Sole power to dispose of or to direct the disposition of: See Row 7 of cover page.

 

iv.Shared power to dispose or to direct the disposition of: See Row 8 of cover page.

 

Item 5.

Ownership of Five Percent or Less of a Class

 

Not applicable.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

 

Not applicable.

 

 

 

 

CUSIP No. 377322102

 

SCHEDULE 13G Page 4 of 5 Pages

 

Item 7.Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

 

Not applicable.

 

Item 8.Identification and Classification of Members of the Group

 

Not applicable.

 

Item 9.Notice of Dissolution of Group

 

Not applicable.

 

Item 10.Certifications

 

Not applicable.

 

 

 

  

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2023

 

  Thomas W. Burns
 
  /s/ Thomas W. Burns

 

 

 

Get the next $GKOS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GKOS

DatePrice TargetRatingAnalyst
2/19/2025$140.00 → $200.00Neutral → Outperform
Mizuho
12/11/2024$132.00 → $162.00Neutral → Buy
Citigroup
12/6/2024$182.00Buy
UBS
12/2/2024$120.00Equal-Weight → Underweight
Morgan Stanley
7/10/2024$132.00Buy → Neutral
Citigroup
5/6/2024$84.00 → $125.00Hold → Buy
Jefferies
12/21/2023$66.00 → $91.00Neutral → Overweight
JP Morgan
12/4/2023$65.00Equal-Weight
Morgan Stanley
More analyst ratings

$GKOS
Press Releases

Fastest customizable press release news feed in the world

See more
  • RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

    Industry Leaders Partner to Advance Vision Testing and Digital Solutions to Expand Patient Access to Eye Care Globally Topcon Healthcare, Inc., RadiusXR, and Glaukos Corporation (NYSE:GKOS) announced a new collaboration and the launch of RadiusXR's new wearable vision testing platform - Inspire®. This collaboration unites RadiusXR's innovative visual field platform and Topcon Healthcare's global leadership in robotic diagnostics and digital healthcare solutions with Glaukos' commitment to expanding patient access by democratizing the diagnosis of ophthalmic diseases such as glaucoma. Together, the companies aim to expand access and enable doctors to provide visual field exams and education

    $GKOS
    Medical/Dental Instruments
    Health Care
  • Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

    PDUFA Date Set for October 20, 2025 Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the "Day 74" notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a sight-threatening corneal disease, is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA's review

    $GKOS
    Medical/Dental Instruments
    Health Care
  • Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024. Key highlights include: Record net sales of $105.5 million in Q4 2024 increased 28% year-over-year. Glaucoma record net sales of $84.1 million in Q4 2024 increased 39% year-over-year. Gross margin of approximately 73% and non-GAAP gross margin of approximately 82% in Q4 2024. Net sales of $383.5 million in FY 2024 increased 22% year-over-year. Introduced 2025 net sales guidance of $475 million to $4

    $GKOS
    Medical/Dental Instruments
    Health Care

$GKOS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GKOS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GKOS
SEC Filings

See more

$GKOS
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for IDOSE TR issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    $GKOS
    Medical/Dental Instruments
    Health Care
  • FDA Approval for TRAVOPROST issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    $GKOS
    Medical/Dental Instruments
    Health Care

$GKOS
Leadership Updates

Live Leadership Updates

See more
  • OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

    NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se

    $BLU
    $GKOS
    $INSP
    $NTLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

    Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos' Board and has served as Chairman since June 2001. In connection with Dr. Link's retirement, the Board has appointed Thomas W. Burns, Glaukos' President and Chief Executive Officer and a director on the Board since 2002, to serve as the company's Chairman of the Board, effective upon Dr. Link's retirement on December 31, 2021. Mr. Burns will continue to serve as th

    $GKOS
    Medical/Dental Instruments
    Health Care
  • Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. “We are delighted and honored to welcome these highly accomplished professionals to the Glaukos Board. Each of these extraordinary women brings a wealth of relevant experience, perspective, leadership and wis

    $GKOS
    Medical/Dental Instruments
    Health Care

$GKOS
Financials

Live finance-specific insights

See more
  • Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024. Key highlights include: Record net sales of $105.5 million in Q4 2024 increased 28% year-over-year. Glaucoma record net sales of $84.1 million in Q4 2024 increased 39% year-over-year. Gross margin of approximately 73% and non-GAAP gross margin of approximately 82% in Q4 2024. Net sales of $383.5 million in FY 2024 increased 22% year-over-year. Introduced 2025 net sales guidance of $475 million to $4

    $GKOS
    Medical/Dental Instruments
    Health Care
  • Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

    Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2024 financial results after the market close on Thursday, February 20, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 20, 2025. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.

    $GKOS
    Medical/Dental Instruments
    Health Care
  • Glaukos Announces Third Quarter 2024 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2024. Key highlights for the third quarter of 2024 include: Record net sales of $96.7 million increased 24% year-over-year. Glaucoma record net sales of $76.0 million increased 30% year-over-year. Corneal Health net sales of $20.6 million increased 5% year-over-year. Gross margin of approximately 77% and non-GAAP gross margin of approximately 82%. Raised 2024 net sales guidance to $377 million to $379 million, compared

    $GKOS
    Medical/Dental Instruments
    Health Care

$GKOS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more